{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:35:37Z","timestamp":1778034937050,"version":"3.51.4"},"reference-count":25,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,9,29]]},"DOI":"10.18632\/oncotarget.4830","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T17:43:03Z","timestamp":1443548583000},"page":"28001-28010","source":"Crossref","is-referenced-by-count":34,"title":["AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair"],"prefix":"10.18632","volume":"6","author":[{"given":"James B.","family":"Ford","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA"},{"name":"University of Nebraska Medical Center, Omaha, Nebraska, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitry","family":"Baturin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara M.","family":"Burleson","sequence":"additional","affiliation":[{"name":"Medical Scientist Training Program, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemie A.","family":"Van Linden","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Mi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Southern California, Los Angeles, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher C.","family":"Porter","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,8,10]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nri2304","article-title":"Molecular pathogenesis of T-cell leukaemia and lymphoma","volume":"8","author":"Buonamici","year":"2008","journal-title":"Nature reviews Immunology"},{"key":"2","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1172\/JCI61269","article-title":"The molecular basis of T cell acute lymphoblastic leukemia","volume":"122","author":"Ferrando","year":"2012","journal-title":"J Clin Invest"},{"key":"3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Carroll","year":"2012","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2003.10.116","article-title":"Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience","volume":"21","author":"Asselin","year":"2003","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/pbc.20429","article-title":"Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296","volume":"46","author":"Amylon","year":"2006","journal-title":"Pediatric blood & cancer"},{"key":"6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)","volume":"118","author":"Camitta","year":"2011","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/j.1460-2075.1993.tb05633.x","article-title":"Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15","volume":"12","author":"Russell","year":"1993","journal-title":"Embo J"},{"key":"8","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1126\/science.1384126","article-title":"Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase","volume":"257","author":"Piwnica-Worms","year":"1992","journal-title":"Science"},{"key":"9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/leu.2011.392","article-title":"Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia","volume":"26","author":"DeGregori","year":"2012","journal-title":"Leukemia"},{"key":"10","article-title":"RNAi screening of the kinome with cytarabine in leukemias","author":"Azorsa","year":"2012","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1535-7163.MCT-13-0424","article-title":"Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeuticsand, independent of p53 functionality","volume":"12","author":"Porter","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"12","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","article-title":"Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents","volume":"8","author":"Jiang","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature07849","article-title":"Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions","volume":"458","author":"Rosenfeld","year":"2009","journal-title":"Nature"},{"key":"14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","article-title":"A three-dimensional model to analyze drug-drug interactions","volume":"14","author":"Shipman","year":"1990","journal-title":"Antiviral research"},{"key":"16","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Grant","year":"2010","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Plunkett","year":"2008","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood-2005-08-3351","article-title":"Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blastsand during a clinical trial","volume":"107","author":"Plunkett","year":"2006","journal-title":"Blood"},{"key":"19","first-page":"1065","article-title":"S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine","volume":"61","author":"Plunkett","year":"2001","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1158\/1078-0432.CCR-12-2442","article-title":"Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias","volume":"18","author":"Gladstone","year":"2012","journal-title":"Clin Cancer Res"},{"key":"21","article-title":"A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin or carboplatin in patients with advanced solid tumors","volume":"28","author":"Oza","year":"2010","journal-title":"J Clin Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/pbc.25081","article-title":"Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia","volume":"61","author":"Taub","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"23","article-title":"Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies","author":"Griffin","year":"2014","journal-title":"Leukemia"},{"key":"24","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1038\/onc.2012.296","article-title":"Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination","volume":"32","author":"van Vugt","year":"2013","journal-title":"Oncogene"},{"key":"25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-6-10","article-title":"Bioluminescence imaging of leukemia cell linesand in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission","volume":"6","author":"Graham","year":"2013","journal-title":"Journal of hematology & oncology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T16:30:51Z","timestamp":1589387451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,10]]},"references-count":25,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2015,9,29]]}},"alternative-id":["4830","26334102"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4830","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,10]]}}}